阿德福韦酯联合干扰素治疗HBeAg阳性慢性乙型肝炎成本-疗效分析  

Cost-curative effect analysis of Adefovir plus Interferon in treating patients with HBeAg-positive chronic hepatitis B

作　　者：岳怀献[1] 王晓彦[1] 白启强[1] 

机构地区：[1]延安大学附属医院药剂科,陕西延安716000

出　　处：《实用临床医药杂志》2011年第17期116-118,共3页Journal of Clinical Medicine in Practice

基　　金：中国高校医学期刊临床专项资金资助项目(11120015)

摘　　要：目的评价阿德福韦酯联合干扰素治疗HBeAg阳性慢性乙型肝炎所产生的经济效果。方法对本院收治的89例HBeAg阳性慢性乙型肝炎分成2种药物治疗方案,即联合用药组(阿德福韦酯+干扰素)、单用药组(阿德福韦酯)。应用药物经济学观点进行成本-效果比较分析。结果联合用药组和单用药组治疗总有效率为74.47%和42.86%,药品成本-疗效(C/E)为23.14和31.50。结论阿德福韦酯联合干扰素治疗慢性乙型肝炎效果良好,成本-疗效较低,值得在临床上推广。Objective To investigate economic effect of Adefovir plus Interferon in treating patients with HBeAg-positive chronic hepatitis B.Methods Eighty-nine patients with HBeAg-positive chronic hepatitis B in our hospital were divided into two groups： Combination group（Adefovir plus Interferon） and Single pill group（Adefovir）.Comparative cost-curative effect analysis of the two groups was carried according to the principles of pharmaceutical economics.Results The total effective rate for combination group and single pill group were 74.47% and 42.86%.Cost-curative effects（C/E） were 23.14 and 31.50 respectively.Conclusion The therapeutic effect of Adefovir plus Interferon in treating chronic hepatitis B is remarkable,its cost-curative effect is low,and it is worth to be popularized clinically.

关 键 词：阿德福韦酯 干扰素 慢性乙型肝炎 成本-效果分析 

分 类 号：R512.6[医药卫生—内科学]